Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma
暂无分享,去创建一个
T Hielscher | B Wagner | D. Hose | H. Goldschmidt | A. Jauch | S. Delorme | T. Hielscher | M. Weber | M. Merz | K. Neben | J. Hillengass | M. Raab | A Jauch | G. Egerer | M-A Weber | J Hillengass | K Neben | S Delorme | H Goldschmidt | S. Sauer | B. Wagner | S. Shah | Sofia Shah | S Shah | M Merz | S Sauer | M S Raab | D Hose | G Egerer | S. Shah | Sandra Sauer | Stefan Delorme | M. Weber
[1] H. Kauczor,et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. , 2009, Radiology.
[2] M. Dimopoulos,et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients , 2012, American journal of hematology.
[3] Tobias Bäuerle,et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Therneau,et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.
[5] E. Giné,et al. Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.
[6] T. Therneau,et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.
[7] R. Fonseca,et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma , 2013, Leukemia.
[8] E Terpos,et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.
[9] A. Órfão,et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.
[10] S. Kristinsson,et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. , 2011, Blood.
[11] B. Barlogie,et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.
[12] F. Prósper,et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.
[13] D. Hose,et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma , 2012, Haematologica.
[14] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.
[15] E. Zamagni,et al. The role of imaging techniques in the management of multiple myeloma , 2012, British journal of haematology.
[16] M. Dimopoulos,et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease , 2013, Leukemia.
[17] M. Dimopoulos,et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] O. Landgren,et al. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma” , 2013, Leukemia & lymphoma.
[19] M. Dimopoulos,et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Hose,et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Guermazi,et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.
[22] B. Barlogie,et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Reiser,et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.
[24] M. Dimopoulos,et al. Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Choyke,et al. Current and future imaging modalities for multiple myeloma and its precursor states , 2011, Leukemia & lymphoma.